

AXTLE™
(Pemetrexed for Injection)

BILLING AND CODING GUIDE

If you have additional billing and coding questions, please call your Field Reimbursement Manager or AVYXASSIST™ at 866-939-8927. Our Patient Access Specialists are available to assist Monday through Friday, 8 AM to 8 PM ET.

Please see Important Safety Information on pages 3 and 13-19 and full [Prescribing Information](#) for AXTLE™.



TABLE OF CONTENTS

Indications and Important Safety Information	3,13 - 19
AXTLE™ Ordering Information	4
AVYXASSIST™ Patient Support Program	5
Billing and Coding Information	6 - 8
NDCs for AXTLE™	6
HCPCS Code	6
AXTLE™ J-Code Billing Unit Conversion	6
CPT Drug Administration Codes	7
ICD Diagnosis Codes	7
ICD Diagnosis Code Descriptions	8
Sample Claim Form CMS-1450 (UB-04)	9 - 10
Sample Claim Form CMS-1500	11 - 12
Important Safety Information, Continued	13 - 19
Notes	20

The contents herein provide general coverage, coding, and payment information about AXTLE™. The information within this guide was obtained from third-party sources and is made available for reference only. It is not exhaustive, is subject to change, and does not constitute billing, coding, or legal advice. Healthcare professionals are responsible for determining which code(s), charge(s), or modifier(s), if any, appropriately reflect a service or diagnosis. It is the healthcare professional's responsibility to determine medical necessity and provide adequate documentation. AVYXA™ does not guarantee coverage or payment. Payment and coverage vary by payer. Questions about coding, coverage, and payment may be directed to the applicable third-party payer, reimbursement specialist, and/or legal counsel.

CMS: Centers for Medicare & Medicaid Services; CPT: Current Procedural Terminology; HCPCS: Healthcare Common Procedure Coding System; ICD: International Classification of Diseases; NDC: National Drug Cod

Please see Important Safety Information on pages 3 and 13-19 and full [Prescribing Information](#) for AXTLE™.

INDICATIONS AND IMPORTANT SAFETY INFORMATION

INDICATIONS

Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

AXTLE™ is indicated for:

- in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non-squamous NSCLC
- as a single agent for the maintenance treatment of patients with locally advanced or metastatic, non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy
- as a single agent for the treatment of patients with recurrent, metastatic non-squamous, NSCLC after prior chemotherapy

Limitations of Use: AXTLE™ is not indicated for the treatment of patients with squamous cell, non-small cell lung cancer.

Mesothelioma

AXTLE™ is indicated, in combination with cisplatin, for the initial treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

AXTLE™ is contraindicated in patients with a history of severe hypersensitivity reaction to pemetrexed.

WARNINGS AND PRECAUTIONS

Myelosuppression and Increased Risk of Myelosuppression without Vitamin Supplementation

AXTLE™ can cause severe myelosuppression resulting in a requirement for transfusions and which may lead to neutropenic infection. The risk of myelosuppression is increased in patients who do not receive vitamin supplementation. In Study JMCH incidences of Grade 3-4 neutropenia (38% versus 23%), thrombocytopenia (9% versus 5%), febrile neutropenia (9% versus 0.6%), and neutropenic infection (6% versus 0) were higher in patients who received pemetrexed plus cisplatin without vitamin supplementation as compared to patients who were fully supplemented with folic acid and vitamin B₁₂ prior to and throughout pemetrexed plus cisplatin treatment.

Initiate supplementation with oral folic acid and intramuscular vitamin B₁₂ prior to the first dose of AXTLE™; continue vitamin supplementation during treatment and for 21 days after the last dose of AXTLE™ to reduce the severity of hematologic and gastrointestinal toxicity of AXTLE™. Obtain a complete blood count at the beginning of each cycle. Do not administer AXTLE™ until the ANC is at least 1500 cells/mm³ and platelet count is at least 100,000 cells/mm³. Permanently reduce AXTLE™ in patients with an ANC of less than 500 cells/mm³ or platelet count of less than 50,000 cells/mm³ in previous cycles.

In Studies JMDB and JMCH, among patients who received vitamin supplementation, incidence of Grade 3-4 neutropenia was 15% and 23%, the incidence of Grade 3-4 anemia was 6% and 4%, and incidence of Grade 3-4 thrombocytopenia was 4% and 5%, respectively. In Study JMCH, 18% of patients in the pemetrexed arm required red blood cell transfusions compared to 7% of patients in the cisplatin arm. In Studies JMEN, PARAMOUNT, and JMEI, where all patients received vitamin supplementation, incidence of Grade 3-4 neutropenia ranged from 3% to 5%, and incidence of Grade 3-4 anemia ranged from 3% to 5%.

AXTLE™ (Pemetrexed for Injection)

Ordering Information

To order AXTLE™ (Pemetrexed for Injection), please contact one of these authorized specialty distributors and use the appropriate order number:



100 mg/vial
NDC: 83831-0131-01



500 mg/vial
NDC: 83831-0132-01

Institutions/Hospitals	100 mg/vial	500 mg/vial
Cardinal Health Specialty	5962121	5962139
CENCORA - ASD Healthcare	10295451	10295442
McKesson Plasma & Biologics	3005485	3005410
Physician Office	100 mg/vial	500 mg/vial
Cardinal Health Specialty	5962121	5962139
Oncology Supply	10295426	10295460
McKesson Specialty Health	5019191	5019190

Highlights¹

- Available as pemetrexed dipotassium
- Free from preservative
- Reconstitute with 5% Dextrose Injection, USP (preservative-free)
- Not made with natural rubber latex
- Unique J-Code: J9292



Please see Important Safety Information on pages 3 and 13-19 and full [Prescribing Information](#) for AXTLE™.

Simplifying Patient Access, Providing Comprehensive Support.

AVYXASSIST™ can offer support to qualifying patients in need. The program provides the following services*

- ✓ Benefit verification
- ✓ Prior authorization requirements
- ✓ Appeals process information
- ✓ Referrals to 501(c)(3) foundations when applicable
- ✓ Free product assistance (uninsured or underinsured), bridge supply (coverage delays)
- ✓ Product replacement
- ✓ Copay assistance

COPAY ASSISTANCE PROGRAM

Eligible patients may pay as little as **\$0** per dose*

TO ENROLL, PLEASE CHOOSE ONE OF THE FOLLOWING OPTIONS



Phone

866-939-8927
Monday through Friday
8 AM to 8 PM ET

CALL NOW

OR



Online

Click on the link below
to begin your online
enrollment

ENROLL NOW

OR



Fax

Download, print and fax
the completed enrollment
form to 833-852-3420

DOWNLOAD NOW

Billing and Coding Information

The information provided is for informational purposes only and represents no statement, promise, or guarantee by AVYXA™ concerning reimbursement, payment, or charges. The information provided is not intended to increase or maximize reimbursement by any payer. Healthcare professionals are responsible for selecting appropriate codes used to file a claim. Codes should be based on the patient's diagnosis and the items and services furnished by the healthcare professional. All codes should be verified between the healthcare professional and the payer. AVYXA™ does not recommend using any particular diagnosis code in any billing situation for AXTLE™ (pemetrexed) for Injection. The below codes are for reference only; coding as submitted is the sole responsibility of the prescribing physician.

NDCs for AXTLE™ FOR INJECTION¹

Nearly all drugs in the United States are given a unique National Drug Code (NDC), which identifies all currently manufactured drugs and is maintained by the FDA.² NDCs are displayed on drug packing in a 10-digit format. Proper NDC billing requires an 11-digit number in a 5-4-2 format, listed below.

NDC	Strength	Vial Size
83831-0131-01	100 mg/vial	Single-dose vial
83831-0132-01	500 mg/vial	Single-dose vial

HCPCS Code³

HCPCS Level II codes are used to identify most drugs and biologics that are given in the office

AXTLE™ Unique J-Code	Description
J9292	Injection, pemetrexed (avyxa), not therapeutically equivalent to J9305, 10 mg

J-Code Billing Unit Conversion

Each 10 milligrams of AXTLE™ equals one (1) billing unit. When billing for quantities greater than 10 milligrams, indicate the total amount used as a multiple of billing units on the claim form. Examples:

One (1) Vial (100 mg)	10 Billing Units
One (1) Vial (500 mg)	50 Billing Units

NOTE: There are a few HCPCS codes for pemetrexed but there is only one HCPCS code for **AXTLE™ (J9292)**, so please make sure the HCPCS code matches the product purchased and administered.

CPT Drug Administration Codes^{4,5}

CPT codes are used to bill drug administration services provided in the physician's office and other outpatient settings

CPT Code	Description
96413	Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug.
96417	Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour.

CPT codes, descriptions, and other data only are copyright 2022 American Medical Association. All Rights Reserved. Applicable FARS/ HHSARS apply. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

AXTLE™ is packaged as a single-dose vial. Medicare will pay for drug waste on single-use items that are medically necessary and appropriately documented in the patient's medical record.

Medicare requires discarded drugs to be reported with the JW modifier on a separate line; if there is no waste, AXTLE™ must be billed on one line with modifier JZ. Medicare requires this; please ascertain if other payers require JZ and JW modifiers ⁶

ICD Diagnosis Codes^{7,8}

For Drugs with multiple indications, it is best practice to code the most specific ICD-10-CM Code within the indication to justify medical necessity.

International Classification of Disease, 10th Edition, Clinical Modification Codes for AXTLE™	
Indication	ICD-10-CM Codes
Non-Small Cell Lung Cancer	C33, C34.00, C34.01, C34.02, C34.10, C34.11, C34.12, C34.2, C34.30, C34.31, C34.32, C34.80, C34.81, C34.82, C34.90, C34.91, C34.92
Mesothelioma	C45.0

AXTLE™ Billing and Coding Information: ICD Diagnosis Codes by Indication

ICD-10-CM coding for AXTLE™ varies greatly by payer. Please check with each payer to ascertain the best coding for AXTLE™ according to their policy.

Non-Small Cell Lung Cancer: ICD-10-CM Diagnosis Coding	
ICD-10 Code	Descriptor
C33	Malignant neoplasm of trachea
C34.00	Malignant neoplasm of unspecified main bronchus
C34.01	Malignant neoplasm of right main bronchus
C34.02	Malignant neoplasm of left main bronchus
C34.10	Malignant neoplasm of upper lobe, unspecified bronchus or lung
C34.11	Malignant neoplasm of upper lobe, right bronchus or lung
C34.12	Malignant neoplasm of upper lobe, left bronchus or lung
C34.2	Malignant neoplasm of middle lobe, bronchus or lung
C34.30	Malignant neoplasm of lower lobe, unspecified bronchus or lung
C34.31	Malignant neoplasm of lower lobe, right bronchus or lung
C34.32	Malignant neoplasm of lower lobe, left bronchus or lung
C34.80	Malignant neoplasm of overlapping sites of unspecified bronchus and lung
C34.81	Malignant neoplasm of overlapping sites of right bronchus and lung
C34.82	Malignant neoplasm of overlapping sites of left bronchus and lung
C34.90	Malignant neoplasm of unspecified part of unspecified bronchus or lung
C34.91	Malignant neoplasm of unspecified part of right bronchus or lung
C34.92	Malignant neoplasm of unspecified part of left bronchus or lung

Mesothelioma: ICD-10-CM Diagnosis Coding	
ICD-10 Code	Descriptor
C45.0	Mesothelioma of pleura

SAMPLE UB-O4 / CMS 1450 Claim Form

Form Locator (FL) 42

(Electronic Claim Form = Loop 2400, Segment Type SV201):

List the appropriate revenue code for the drug. Match the descriptor for AXTLE™ for Injection to your revenue code, 0636.

Additionally, enter an appropriate revenue code for the administration service, 0335 for chemotherapy, or others based on the cost center in which the service was performed.

FL 43

(NOT REQUIRED BY MEDICARE):

Enter the description of the procedure for the Revenue Code billed.

If the patient is dualeligible, the N4 indicator first, then the 11-digit NDC code. In the third place, list the quantity and, last, the unit measurement code. Check with other payers for their requirements.

FL 44

(Electronic Claim Form = Loop 2400, SV202-2 (SV202-1=HC/HP):

Enter the appropriate HCPCS code, J9292, Injection, pemetrexed (avyxa), not therapeutically equivalent to J9305, 10 mg.

AXTLE™ is packaged as a single-dose vial. Medicare requires drug waste be reported with the JW¹ modifier on a separate line. If there is no waste, AXTLE™ must be billed on one line with modifier JZ.² Medicare requires this; please ascertain if other payers require JZ and JW modifiers.

For administration, enter the appropriate code or codes for the infusion duration. As an example, a 60-minute infusion of chemotherapy requires 96413.³

FL 42

FL 44

1 PATIENT NAME		2 PATIENT ADDRESS		3a PAY CNTL # 3b MED REC #		4 TOP OF BILL	
5 FED. TAX NO.		6 STATEMENT COVERS PERIOD FROM		7 THROUGH			
8 PATIENT NAME		9 PATIENT ADDRESS		10 BIRTHDATE		11 SEX	
12 DATE		13 HR		14 TYPE		15 SRC	
16 DHR		17 STAT		18		19	
20		21		22		23	
24		25		26		27	
28		29		30		31	
32		33		34		35	
36		37		38		39	
40		41		42		43	
44		45		46		47	
48		49		50		51	
52		53		54		55	
56		57		58		59	
60		61		62		63	
64		65		66		67	
68		69		70		71	
72		73		74		75	
76		77		78		79	
80		81		82		83	
84		85		86		87	
88		89		90		91	
92		93		94		95	
96		97		98		99	
100		101		102		103	
104		105		106		107	
108		109		110		111	
112		113		114		115	
116		117		118		119	
120		121		122		123	
124		125		126		127	
128		129		130		131	
132		133		134		135	
136		137		138		139	
140		141		142		143	
144		145		146		147	
148		149		150		151	
152		153		154		155	
156		157		158		159	
160		161		162		163	
164		165		166		167	
168		169		170		171	
172		173		174		175	
176		177		178		179	
180		181		182		183	
184		185		186		187	
188		189		190		191	
192		193		194		195	
196		197		198		199	
200		201		202		203	
204		205		206		207	
208		209		210		211	
212		213		214		215	
216		217		218		219	
220		221		222		223	
224		225		226		227	
228		229		230		231	
232		233		234		235	
236		237		238		239	
240		241		242		243	
244		245		246		247	
248		249		250		251	
252		253		254		255	
256		257		258		259	
260		261		262		263	
264		265		266		267	
268		269		270		271	
272		273		274		275	
276		277		278		279	
280		281		282		283	
284		285		286		287	
288		289		290		291	
292		293		294		295	
296		297		298		299	
300		301		302		303	
304		305		306		307	
308		309		310		311	
312		313		314		315	
316		317		318		319	
320		321		322		323	
324		325		326		327	
328		329		330		331	
332		333		334		335	
336		337		338		339	
340		341		342		343	
344		345		346		347	
348		349		350		351	
352		353		354		355	
356		357		358		359	
360		361		362		363	
364		365		366		367	
368		369		370		371	
372		373		374		375	
376		377		378		379	
380		381		382		383	
384		385		386		387	
388		389		390		391	
392		393		394		395	
396		397		398		399	
400		401		402		403	
404		405		406		407	
408		409		410		411	
412		413		414		415	
416		417		418		419	
420		421		422		423	
424		425		426		427	
428		429		430		431	
432		433		434		435	
436		437		438		439	
440		441		442		443	
444		445		446		447	
448		449		450		451	
452		453		454		455	
456		457		458		459	
460		461		462		463	
464		465		466		467	
468		469		470		471	
472		473		474		475	
476		477		478		479	
480		481		482		483	
484		485		486		487	
488		489		490		491	
492		493		494		495	
496		497		498		499	
500		501		502		503	
504		505		506		507	
508		509		510		511	
512		513		514		515	
516		517		518		519	
520		521		522		523	
524		525		526		527	
528		529		530		531	
532		533		534		535	
536		537		538		539	
540		541		542		543	
544		545		546		547	
548		549		550		551	
552		553		554		555	
556		557		558		559	
560		561		562		563	
564		565		566		567	
568		569		570		571	
572		573		574		575	
576		577		578		579	
580		581		582		583	
584		585		586		587	
588		589		590		591	
592		593		594		595	
596		597		598		599	
600		601		602		603	
604		605		606		607	
608		609		610		611	
612		613		614		615	
616		617		618		619	
620		621		622		623	
624		625		626		627	
628		629		630		631	
632		633		634		635	
636		637		638		639	
640		641		642		643	
644		645		646		647	
648		649		650		651	
652		653		654		655	
656		657		658		659	
660		661		662		663	
664		665		666		667	
668		669		670		671	
672		673		674		675	
676		677		678		679	
680		681		682		683	
684		685		686		687	
688		689		690		691	
692		693		694		695	
696		697		698		699	
700		701		702		703	
704		705		706		707	
708		709		710		711	
712		713		714		715	
716		717		718		719	
720		721		722		723	
724		725		726		727	
728		729		730		731	
732		733		734		735	
736		737		738		739	
740		741		742		743	
744		745		746		747	
748		749		750		751	
752		753		754		755	
756		757		758		759	
760		761		762		763	
764		765		766		767	
768		769		770		771	
772		773		774		775	
776		777		778		779	
780		781		782		783	
784		785		786		787	
788		789		790		791	
792		793		794		795	
796		797		798		799	
800		801		802		803	
804		805		806		807	
808		809		810		811	
812		813		814		815	
816		817		818		819	
820		821		822		823	
824		825		826		827	
828		829		830		831	

FL 45

(Electronic Claim Form = Loop 2400, Segment DTP/472/03):

Enter the date of service

FL 46

(Electronic Claim Form = Loop 2400, SV205):

Enter the units for the HCPCS code billed. Enter the number of service units for each item.

For example, 10 units if using one 100 mg/vial, or 50 units if using one 500 mg/vial of AXTLE™ (pemetrexed) for injection.

FL 63

(Electronic Claim Form = Loop 2300, REF/G1/02):

Enter treatment authorization code.

FL 67A-Q

(Electronic Claim Form = Loop 2300, HI01-2 (HI01-1=BK):

Enter a diagnosis code for the drug documented in the medical record. Be as specific as possible.

The code listed here is an example: **C34.01, Malignant neoplasm of right main bronchus.**

[1] Since January 1, 2017, Medicare has required Modifier -JW for waste. Check with other payers as to their requirements for identifying waste.

[2] Effective July 1, 2023, Medicare requires the JZ modifier on all claims for single-dose containers with no discarded amounts.

[3]] CPT Code 96413 Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug Initial infusion times may vary.

Electronic Claims Reference: ASC 837I Version 5010A2 Institutional Health Care Claim to the CMS-1450 Claim Form Crosswalk." Palmettogba.Com. Palmetto GBA, Accessed April 3, 2023. [https://www.palmettogba.com/palmetto/providers.nsf/files/EDI_837I_v5010A2_crosswalk.pdf/\\$FILE/EDI_837I_v5010A2_crosswalk.pdf](https://www.palmettogba.com/palmetto/providers.nsf/files/EDI_837I_v5010A2_crosswalk.pdf/$FILE/EDI_837I_v5010A2_crosswalk.pdf)

CPT Codes are a registered trademark of the American Medical Association (AMA), All Rights Reserved

THIS INFORMATION IS PROVIDED FOR EDUCATIONAL PURPOSES ONLY AND IS NOT A GUARANTEE OF COVERAGE. IT IS THE SOLE RESPONSIBILITY OF THE HEALTH CARE PROVIDER TO SELECT THE PROPER CODES AND ENSURE THE ACCURACY OF ALL STATEMENTS USED IN SEEKING COVERAGE AND REIMBURSEMENT FOR AN INDIVIDUAL PATIENT.

SAMPLE CMS 1500 Claim Form

Box 21

(Electronic Claim Form = Loop 2300, Segment H101-2 through H112=2):

Enter the patient's diagnosis from the patient's medical record. An example code for this drug is **C34.01, Malignant neoplasm of right main bronchus**

Use Box 21 B-L fields for secondary diagnoses.

Box 23

(Electronic Claim Form = Loop 2300, REF02):

Enter prior authorization number if one exists.

Box 24D

(Electronic Claim Form = Loop 2400, Segment SV101):

Enter the appropriate HCPCS code, **J9292, Injection, pemetrexed (avyxa), not therapeutically equivalent to J9305, 10 mg.**

AXTLE™ is packaged as a single-dose vial. Medicare requires drug waste be reported with the -JW¹ modifier on a separate line. If there is no waste, AXTLE™ must be billed on one line with modifier -JZ.² Medicare requires this; please ascertain if other payers require JZ and -JW modifiers.

For administration, enter the appropriate code or codes for the infusion duration. As an example, a 60-minute infusion of chemotherapy requires 96413.³

Box 24E

(Electronic Claim Form = Loop 2400, Segment SV107):

Specify the diagnosis letter that corresponds with the drug and administration code(s) in Box 21.



HEALTH INSURANCE CLAIM FORM

APPROVED BY NATIONAL UNIFORM CLAIM COMMITTEE (NUCC) 02/12

1. MEDICARE <input type="checkbox"/> MEDICAID <input type="checkbox"/> TRICARE <input type="checkbox"/> CHAMPVA <input type="checkbox"/> GROUP HEALTH PLAN <input type="checkbox"/> FECA BOX (LUNG) <input type="checkbox"/> OTHER <input type="checkbox"/>		1a. INSURED'S I.D. NUMBER (For Program in Item 1)	
2. PATIENT'S NAME (Last Name, First Name, Middle Initial)		3. PATIENT'S BIRTH DATE MM DD YY SEX M <input type="checkbox"/> F <input type="checkbox"/>	
5. PATIENT'S ADDRESS (No., Street)		6. PATIENT RELATIONSHIP TO INSURED Self <input type="checkbox"/> Spouse <input type="checkbox"/> Child <input type="checkbox"/> Other <input type="checkbox"/>	
CITY		CITY	
STATE		STATE	
ZIP CODE		ZIP CODE	
TELEPHONE (Include Area Code)		TELEPHONE (Include Area Code)	
9. OTHER INSURED'S NAME (Last Name, First Name, Middle Initial)		10. IS PATIENT'S CONDITION RELATED TO:	
a. OTHER INSURED'S POLICY OR GROUP NUMBER		a. EMPLOYMENT? (Current or Previous) YES <input type="checkbox"/> NO <input type="checkbox"/>	
b. RESERVED FOR NUCC USE		b. AUTO ACCIDENT? YES <input type="checkbox"/> NO <input type="checkbox"/> PLACE (State)	
c. RESERVED FOR NUCC USE		c. OTHER ACCIDENT? YES <input type="checkbox"/> NO <input type="checkbox"/>	
d. INSURANCE PLAN NAME OR PROGRAM NAME		10d. CLAIM CODES (Designated by NUCC)	
12. PATIENT'S OR AUTHORIZED PERSON'S SIGNATURE (I authorize the release of any medical or other information necessary to process this claim. I also request payment of government benefits either to myself or to the party who accepts assignment below.)		13. INSURED'S OR AUTHORIZED PERSON'S SIGNATURE (I authorize payment of medical benefits to the undersigned physician or supplier for services described below.)	
SIGNED _____ DATE _____		SIGNED _____ DATE _____	
14. DATE OF CURRENT ILLNESS, INJURY, OR PREGNANCY (LMP) FROM MM DD YY TO MM DD YY QUAL		15. OTHER DATE QUAL MM DD YY	
17. NAME OF REFERRING PROVIDER OR OTHER SOURCE		18. HOSPITALIZATION DATES RELATED TO CURRENT SERVICES FROM MM DD YY TO MM DD YY	
19. ADDITIONAL CLAIM INFORMATION (Designated by NUCC)		20. OUTSIDE LAB? YES <input type="checkbox"/> NO <input type="checkbox"/> \$ CHARGES	
21. DIAGNOSIS OR NATURE OF ILLNESS OR INJURY. Relate A-L to service line below (24D)		22. RESUBMISSION CODE	
A. _____ B. _____ C. _____ D. _____		23. PRIOR AUTHORIZATION NUMBER	
E. _____ F. _____ G. _____ H. _____		24. A. DATE(S) OF SERVICE FROM MM DD YY TO MM DD YY	
I. _____ J. _____ K. _____ L. _____		D. PROCEDURES, SERVICES, OR SUPPLIES (Explain Unusual Circumstances) OPT/PCS MODIFIER	
25. FEDERAL TAX I.D. NUMBER SSN EIN		26. PATIENT'S ACCOUNT NO.	
27. ACCEPT ASSIGNMENT? (For govt. claims, see back) YES <input type="checkbox"/> NO <input type="checkbox"/>		28. TOTAL CHARGE \$	
29. AMOUNT PAID \$		30. Paid for NUCC Use	
31. SIGNATURE OF PHYSICIAN OR SUPPLIER INCLUDING DEGREE(S) OR CREDENTIALS (I certify that the statements on the reverse apply to this bill and are made a part thereof.)		32. SERVICE FACILITY LOCATION INFORMATION	
SIGNED _____ DATE _____		a. NPI b. _____	
33. BILLING PROVIDER INFO & PH # ()		a. NPI b. _____	

Box 24G

(Electronic Claim Form = Loop 2400, SV104):

Enter the number of service units for each item.

Box 24A-B

Box 24A-B (Electronic Claim Form: Box 24A (Electronic Claims = Loop 2400, DTP02; Box 24 B (Loop 2300/2400, Segment CLM05-1/SV105)

In the non-shaded area, enter the appropriate date of service and place of service code.
Example: Office = 11

In the shaded area, enter the N4 indicator first, then the 11-digit NDC code. In the third space, list the quantity and, last, the unit measurement code

Box 24A-B**HEALTH INSURANCE CLAIM FORM**

APPROVED BY NATIONAL UNIFORM CLAIM COMMITTEE (NUCC) 02/12

<div style="display: flex; justify-content: space-between;"> <div> <input type="checkbox"/> PICA </div> <div> <input type="checkbox"/> PICA </div> </div>											
1. MEDICARE <input type="checkbox"/> MEDICAID <input type="checkbox"/> TRICARE <input type="checkbox"/> CHAMPVA <input type="checkbox"/> GROUP HEALTH PLAN (ID#) <input type="checkbox"/> FECA BLK LUNG (ID#) <input type="checkbox"/> OTHER (ID#) <input type="checkbox"/>						1a. INSURED'S I.D. NUMBER (For Program in Item 1)					
2. PATIENT'S NAME (Last Name, First Name, Middle Initial)						3. PATIENT'S BIRTH DATE MM DD YY			4. INSURED'S NAME (Last Name, First Name, Middle Initial)		
5. PATIENT'S ADDRESS (No., Street)						6. PATIENT RELATIONSHIP TO INSURED Self <input type="checkbox"/> Spouse <input type="checkbox"/> Child <input type="checkbox"/> Other <input type="checkbox"/>			7. INSURED'S ADDRESS (No., Street)		
CITY STATE						CITY STATE			CITY STATE		
ZIP CODE TELEPHONE (Include Area Code)						ZIP CODE TELEPHONE (Include Area Code)			ZIP CODE TELEPHONE (Include Area Code)		
9. OTHER INSURED'S NAME (Last Name, First Name, Middle Initial)						10. IS PATIENT'S CONDITION RELATED TO:			11. INSURED'S POLICY GROUP OR FECA NUMBER		
a. OTHER INSURED'S POLICY OR GROUP NUMBER						a. EMPLOYMENT? (Current or Previous) <input type="checkbox"/> YES <input type="checkbox"/> NO			a. INSURED'S DATE OF BIRTH MM DD YY SEX M <input type="checkbox"/> F <input type="checkbox"/>		
b. RESERVED FOR NUCC USE						b. AUTO ACCIDENT? <input type="checkbox"/> YES <input type="checkbox"/> NO PLACE (State)			b. OTHER CLAIM ID (Designated by NUCC)		
c. RESERVED FOR NUCC USE						c. OTHER ACCIDENT? <input type="checkbox"/> YES <input type="checkbox"/> NO			c. INSURANCE PLAN NAME OR PROGRAM NAME		
d. INSURANCE PLAN NAME OR PROGRAM NAME						10d. CLAIM CODES (Designated by NUCC)			d. IS THERE ANOTHER HEALTH BENEFIT PLAN? <input type="checkbox"/> YES <input type="checkbox"/> NO If yes, complete items 9, 9a, and 9d.		
READ BACK OF FORM BEFORE COMPLETING & SIGNING THIS FORM.											
12. PATIENT'S OR AUTHORIZED PERSON'S SIGNATURE: I authorize the release of any medical or other information necessary to process this claim. I also request payment of government benefits either to myself or to the party who accepts assignment below.											
SIGNED DATE						SIGNED					
14. DATE OF CURRENT ILLNESS, INJURY, OR PREGNANCY (LMP) MM DD YY QUAL						15. OTHER DATE QUAL MM DD YY			16. DATES PATIENT UNABLE TO WORK IN CURRENT OCCUPATION FROM MM DD YY TO MM DD YY		
17. NAME OF REFERRING PROVIDER OR OTHER SOURCE						17a. NPI			18. HOSPITALIZATION DATES RELATED TO CURRENT SERVICES FROM MM DD YY TO MM DD YY		
19. ADDITIONAL CLAIM INFORMATION (Designated by NUCC)						17b. NPI			20. OUTSIDE LAB? <input type="checkbox"/> YES <input type="checkbox"/> NO \$ CHARGES		
21. DIAGNOSIS OR NATURE OF ILLNESS OR INJURY: Relate A-L to service line below (24B)						ICD Ind			22. RESUBMISSION CODE ORIGINAL REF. NO.		
A. B. C. D. E. F. G. H. I. J. K. L.						23. PRIOR AUTHORIZATION NUMBER			24. A. DATE(S) OF SERVICE From MM DD YY To MM DD YY B. PLACE OF SERVICE C. EMG D. PROCEDURES, SERVICES, OR SUPPLIES (Explain Unusual Circumstances) EPT/HCPCS MODIFIER E. DIAGNOSIS POINTER F. \$ CHARGES G. DAYS OF UNITS H. EPT/HCPCS Rate I. ID. QUAL J. RENDERING PROVIDER ID. #		
25. FEDERAL TAX I.D. NUMBER SSN EIN						26. PATIENT'S ACCOUNT NO.			27. ACCEPT ASSIGNMENT? (or per CMS-1500) YES <input type="checkbox"/> NO <input type="checkbox"/>		
28. TOTAL CHARGE \$						29. AMOUNT PAID \$			30. Paid for NUCC Use		
31. SIGNATURE OF PHYSICIAN OR SUPPLIER INCLUDING DEGREES OR CREDENTIALS (I certify that the statements on the reverse apply to this bill and are made a part thereof.)						32. SERVICE FACILITY LOCATION INFORMATION			33. BILLING PROVIDER INFO & PH #		
SIGNED DATE						a. NPI b.			a. NPI b.		

NUCC Instruction Manual available at: www.nucc.org

PLEASE PRINT OR TYPE

APPROVED OMB-0938-1197 FORM 1500 (02-12)

[1] Since January 1, 2017, Medicare has required Modifier -JW for waste. Check with other payers as to their requirements for identifying waste.

[2] Effective July 1, 2023, Medicare requires the JZ modifier on all claims for single-dose containers with no discarded amounts.

[3] CPT Code 96413 Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug Initial infusion times may vary.

Electronic Claims Reference: ASC 837I Version 5010A2 Institutional Health Care Claim to the CMS-1450 Claim Form Crosswalk." Palmettogba.Com. Palmetto GBA, Accessed April 3, 2023. https://www.palmettogba.com/palmetto/providers.nsf/files/EDI_837I_v5010A2_crosswalk.pdf?FILE/EDI_837I_v5010A2_crosswalk.pdf

CPT Codes are a registered trademark of the American Medical Association (AMA), All Rights Reserved

THIS INFORMATION IS PROVIDED FOR EDUCATIONAL PURPOSES ONLY AND IS NOT A GUARANTEE OF COVERAGE. IT IS THE SOLE RESPONSIBILITY OF THE HEALTH CARE PROVIDER TO SELECT THE PROPER CODES AND ENSURE THE ACCURACY OF ALL STATEMENTS USED IN SEEKING COVERAGE AND REIMBURSEMENT FOR AN INDIVIDUAL PATIENT.

IMPORTANT SAFETY INFORMATION (CONTINUED)

Renal Failure

AXTLE™ can cause severe, and sometimes fatal, renal toxicity. The incidences of renal failure in clinical studies in which patients received pemetrexed with cisplatin were: 2.1% in Study JMDB and 2.2% in Study JMCH. The incidence of renal failure in clinical studies in which patients received pemetrexed as a single agent ranged from 0.4% to 0.6% (Studies JMEN, PARAMOUNT, and JMEI). Determine creatinine clearance before each dose and periodically monitor renal function during treatment with AXTLE™. Withhold AXTLE™ in patients with a creatinine clearance of less than 45 mL/minute.

Bullous and Exfoliative Skin Toxicity

Serious and sometimes fatal, bullous, blistering and exfoliative skin toxicity, including cases suggestive of Stevens-Johnson Syndrome/Toxic epidermal necrolysis can occur with AXTLE™. Permanently discontinue AXTLE™ for severe and life-threatening bullous, blistering or exfoliating skin toxicity.

Interstitial Pneumonitis

Serious interstitial pneumonitis, including fatal cases, can occur with AXTLE™ treatment. Withhold AXTLE™ for acute onset of new or progressive unexplained pulmonary symptoms such as dyspnea, cough, or fever pending diagnostic evaluation. If pneumonitis is confirmed, permanently discontinue AXTLE™.

Radiation Recall

Radiation recall can occur with AXTLE™ in patients who have received radiation weeks to years previously. Monitor patients for inflammation or blistering in areas of previous radiation treatment. Permanently discontinue AXTLE™ for signs of radiation recall.

Increased Risk of Toxicity with Ibuprofen in Patients with Renal Impairment

Exposure to pemetrexed is increased in patients with mild to moderate renal impairment who take concomitant ibuprofen, increasing the risks of adverse reactions of AXTLE™. In patients with creatinine clearances between 45 mL/min and 79 mL/min, avoid administration of ibuprofen for 2 days before, the day of, and 2 days following administration of AXTLE™. If concomitant ibuprofen use cannot be avoided, monitor patients more frequently for pemetrexed adverse reactions, including myelosuppression, renal, and gastrointestinal toxicity.

Embryo-Fetal Toxicity

Based on findings from animal studies and its mechanism of action, AXTLE™ can cause fetal harm when administered to a pregnant woman. In animal reproduction studies, intravenous administration of pemetrexed to pregnant mice during the period of organogenesis was teratogenic, resulting in developmental delays and increased malformations at doses lower than the recommended human dose of 500 mg/m². Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with AXTLE™ and for 6 months after the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with AXTLE™ and for 3 months after the last dose.

IMPORTANT SAFETY INFORMATION (CONTINUED)

ADVERSE REACTIONS

In clinical trials, the most common adverse reactions (incidence $\geq 20\%$) of pemetrexed, when administered as a single agent, are fatigue, nausea, and anorexia. The most common adverse reactions (incidence $\geq 20\%$) of pemetrexed, when administered in combination with cisplatin are vomiting, neutropenia, anemia, stomatitis/pharyngitis, thrombocytopenia, and constipation.

Non-Squamous NSCLC

Initial Treatment in Combination with Cisplatin (Study JMDB)

The safety of pemetrexed was evaluated in chemotherapy-naïve patients with locally advanced or metastatic NSCLC. Patients received either pemetrexed 500 mg/m² intravenously and cisplatin 75 mg/m² intravenously (N=839) or gemcitabine 1250 mg/m² intravenously and cisplatin 75 mg/m² intravenously (N=830).

The following adverse reactions occurred in $\geq 5\%$ of fully vitamin-supplemented patients (with folic acid and vitamin B₁₂) who received pemetrexed in combination with cisplatin chemotherapy compared to those who received gemcitabine in combination with cisplatin, respectively: anemia (33% [6% Grade 3-4] versus 46% [10% Grade 3-4], respectively), neutropenia (29% [15% Grade 3-4] versus 38% [27% Grade 3-4], respectively), thrombocytopenia (10% [4% Grade 3-4] versus 27% [13% Grade 3-4], respectively), elevated creatinine (10% [1% Grade 3-4] versus 7% [1% Grade 3-4], respectively), fatigue (43% [7% Grade 3-4] versus 45% [5% Grade 3-4], respectively), nausea (56% [7% Grade 3-4] versus 53% [4% Grade 3-4], respectively), vomiting (40% [6% Grade 3-4] versus 36% [6% Grade 3-4], respectively), anorexia (27% [2% Grade 3-4] versus 24% [1% Grade 3-4], respectively), constipation (21% [1% Grade 3-4] versus 20% [0% Grade 3-4], respectively), stomatitis/pharyngitis (14% [1% Grade 3-4] versus 12% [0% Grade 3-4], respectively), diarrhea (12% [1% Grade 3-4] versus 13% [2% Grade 3-4], respectively), dyspepsia/heartburn (5% [0% Grade 3-4] versus 6% [0% Grade 3-4], respectively), sensory neuropathy (9% [0% Grade 3-4] versus 12% [1% Grade 3-4], respectively), taste disturbance (8% [0% Grade 3-4] versus 9% [0% Grade 3-4], respectively), alopecia (12% [0% Grade 3-4] versus 21% [1% Grade 3-4], respectively), and rash/desquamation (7% [0% Grade 3-4] versus 8% [1% Grade 3-4], respectively).

The following additional adverse reactions of pemetrexed were observed with an incidence of 1% to $<5\%$: febrile neutropenia, infection, pyrexia, dehydration, increased AST, increased ALT, renal failure, and conjunctivitis.

The following additional adverse reactions of pemetrexed were observed with an incidence of $<1\%$: arrhythmia, chest pain, increased GGT, and motor neuropathy.

Maintenance Treatment Following First-line Non-Pemetrexed Containing Platinum-Based Chemotherapy

The safety of pemetrexed was evaluated in patients with non-progressive locally advanced or metastatic NSCLC following four cycles of a first-line, platinum-based chemotherapy regimen. Patients received either pemetrexed 500 mg/m² (N=438) or matching placebo (N=218) intravenously.

The following adverse reactions occurred in $\geq 5\%$ of fully vitamin-supplemented patients (with folic acid and vitamin B₁₂) who received pemetrexed compared to placebo, respectively: anemia (15% [3% Grade 3-4] versus 6% [1% Grade 3-4], respectively), neutropenia (6% [3% Grade 3-4] versus 0%, respectively), increased ALT (10% [0% Grade 3-4] versus 4% [0% Grade 3-4], respectively), increased AST (8% [0% Grade 3-4] versus 4% [0% Grade 3-4], respectively), fatigue (25% [5% Grade 3-4] versus 11% [1% Grade 3-4], respectively), nausea (19% [1% Grade 3-4] versus 6% [1% Grade 3-4], respectively), anorexia (19% [2% Grade 3-4] versus 5% [0% Grade 3-4], respectively), vomiting (9% [0% Grade 3-4] versus 1% [0% Grade 3-4], respectively), mucositis/stomatitis (7% [1% Grade 3-4] versus 2% [0% Grade 3-4], respectively), diarrhea (5% [1% Grade 3-4] versus 3% [0% Grade 3-4], respectively), sensory neuropathy (9% [1% Grade 3-4] versus 4% [0% Grade 3-4], respectively), and rash/desquamation (10% [0% Grade 3-4] versus 3% [0% Grade 3-4], respectively).

IMPORTANT SAFETY INFORMATION (CONTINUED)

The requirement for transfusions (9.5% versus 3.2%), primarily red blood cell transfusions, and for erythropoiesis stimulating agents (5.9% versus 1.8%) were higher in the pemetrexed arm compared to the placebo arm.

The following additional adverse reactions were observed in 1% to <5% of patients who received pemetrexed: alopecia, pruritis/itching, constipation, edema, fever, thrombocytopenia, ocular surface disease (including conjunctivitis), and increased lacrimation.

The following additional adverse reactions were observed in <1% of patients who received pemetrexed: supraventricular arrhythmia, erythema multiforme, febrile neutropenia, allergic reaction/hypersensitivity, motor neuropathy, and renal failure.

Maintenance Treatment Following First-line Pemetrexed Plus Platinum Chemotherapy

The safety of pemetrexed was evaluated in patients with non-squamous NSCLC with non-progressive (stable or responding disease) locally advanced or metastatic NSCLC following four cycles of pemetrexed in combination with cisplatin as first-line therapy for NSCLC.

The following adverse reactions occurred in ≥5% of fully vitamin-supplemented patients (with folic acid and vitamin B₁₂) who received pemetrexed (500 mg/m²; N=333) intravenously compared to placebo (N=167), respectively: anemia (15% [4.8% Grade 3-4] versus 4.8% [0.6% Grade 3-4], respectively), neutropenia (9% [3.9% Grade 3-4] versus 0.6% [0% Grade 3-4], respectively), fatigue (18% [4.5% Grade 3-4] versus 11% [0.6% Grade 3-4], respectively), nausea (12% [0.3% Grade 3-4] versus 2.4% [0% Grade 3-4], respectively), vomiting (6% [0% Grade 3-4] versus 1.8% [0% Grade 3-4], respectively), mucositis/stomatitis (5% [0.3% Grade 3-4] versus 2.4% [0% Grade 3-4], respectively), and edema (5% [0% Grade 3-4] versus 3.6% [0% Grade 3-4], respectively).

The requirement for red blood cell (13% versus 4.8%) and platelet (1.5% versus 0.6%) transfusions, erythropoiesis stimulating agents (12% versus 7%), and granulocyte colony stimulating factors (6% versus 0%) were higher in the pemetrexed arm compared to the placebo arm.

The following additional Grade 3 or 4 adverse reactions were observed more frequently in patients who received pemetrexed.

At an incidence of 1% to <5%: thrombocytopenia and febrile neutropenia.

At an incidence of <1%: ventricular tachycardia, syncope, pain, gastrointestinal obstruction, depression, renal failure, and pulmonary embolism.

Treatment of Recurrent Disease After Prior Chemotherapy

The safety of pemetrexed was evaluated in patients who had progressed following platinum-based chemotherapy. The following adverse reactions occurred in ≥5% of fully vitamin-supplemented patients (with folic acid and vitamin B₁₂) who received pemetrexed (500 mg/m²; N=265) intravenously compared to those who received docetaxel (75 mg/m²; N=276), respectively: anemia (19% [4% Grade 3-4] versus 22% [4% Grade 3-4], respectively), neutropenia (11% [5% Grade 3-4] versus 45% [40% Grade 3-4], respectively), thrombocytopenia (8% [2% Grade 3-4] versus 1% [0% Grade 3-4], respectively), increased ALT (8% [2% Grade 3-4] versus 1% [0% Grade 3-4], respectively), increased AST (7% [1% Grade 3-4] versus 1% [0% Grade 3-4], respectively), nausea (31% [3% Grade 3-4] versus 17% [2% Grade 3-4], respectively), anorexia (22% [2% Grade 3-4] versus 24% [3% Grade 3-4], respectively), vomiting (16% [2% Grade 3-4] versus 12%

IMPORTANT SAFETY INFORMATION (CONTINUED)

[1% Grade 3-4], respectively), stomatitis/pharyngitis (15% [1% Grade 3-4] versus 17% [1% Grade 3-4], respectively), diarrhea (13% [0% Grade 3-4] versus 24% [3% Grade 3-4], respectively), constipation (6% [0% Grade 3-4] versus 4% [0% Grade 3-4], respectively), fatigue (34% [5% Grade 3-4] versus 36% [5% Grade 3-4], respectively), fever (8% [0% Grade 3-4] versus 8% [0% Grade 3-4], respectively), rash/desquamation (14% [0% Grade 3-4] versus 6% [0% Grade 3-4], respectively), pruritus (7% [0% Grade 3-4] versus 2% [0% Grade 3-4], respectively), and alopecia (6% [1% Grade 3-4] versus 38% [2% Grade 3-4], respectively).

The following additional adverse reactions were observed in 1% to <5% of patients who received pemetrexed: abdominal pain, allergic reaction/hypersensitivity, febrile neutropenia, infection, erythema multiforme, motor neuropathy, and sensory neuropathy.

The following additional adverse reactions were observed in <1% of patients who received pemetrexed: supraventricular arrhythmias, and renal failure.

Mesothelioma

The safety of pemetrexed was evaluated in patients with MPM who had received no prior chemotherapy for MPM. Among 226 patients who received pemetrexed in combination with cisplatin, 74% (n=168) received full supplementation with folic acid and vitamin B₁₂, 14% (n=32) were never supplemented, and 12% (n=26) were partially supplemented. The following adverse reactions occurred in ≥5% of patients who received pemetrexed (500 mg/m²) intravenously in combination with cisplatin (75 mg/m²) intravenously (N=168) compared to those who received cisplatin (75 mg/m²; N=163), respectively: neutropenia (56% [23% Grade 3-4] versus 13% [3% Grade 3-4], respectively), anemia (26% [4% Grade 3-4] versus 10% [0% Grade 3-4], respectively), thrombocytopenia (23% [5% Grade 3-4] versus 9% [0% Grade 3-4], respectively), elevated creatinine (11% [1% Grade 3-4] versus 10% [1% Grade 3-4], respectively), decreased creatinine clearance (16% [1% Grade 3-4] versus 18% [2% Grade 3-4], respectively), conjunctivitis (5% [0% Grade 3-4] versus 1% [0% Grade 3-4], respectively), nausea (82% [12% Grade 3-4] versus 77% [6% Grade 3-4], respectively), vomiting (57% [11% Grade 3-4] versus 50% [4% Grade 3-4], respectively), stomatitis/pharyngitis (23% [3% Grade 3-4] versus 6% [0% Grade 3-4], respectively), anorexia (20% [1% Grade 3-4] versus 14% [1% Grade 3-4], respectively), diarrhea (17% [4% Grade 3-4] versus 8% [0% Grade 3-4], respectively), constipation (12% [1% Grade 3-4] versus 7% [1% Grade 3-4], respectively), dyspepsia (5% [1% Grade 3-4] versus 1% [0% Grade 3-4], respectively), fatigue (48% [10% Grade 3-4] versus 42% [9% Grade 3-4], respectively), dehydration (7% [4% Grade 3-4] versus 1% [1% Grade 3-4], respectively), sensory neuropathy (10% [0% Grade 3-4] versus 10% [1% Grade 3-4], respectively), taste disturbance (8% [0% Grade 3-4] versus 6% [0% Grade 3-4], respectively), rash (16% [1% Grade 3-4] versus 5% [0% Grade 3-4], respectively), and alopecia (11% [0% Grade 3-4] versus 6% [0% Grade 3-4], respectively).

The following additional adverse reactions were observed in 1% to <5% of patients who received pemetrexed in combination with cisplatin: febrile neutropenia, infection, pyrexia, urticaria, chest pain, increased AST, increased ALT, increased GGT, and renal failure.

The following additional adverse reactions were observed in <1% of patients who received pemetrexed in combination with cisplatin: arrhythmia and motor neuropathy.

Exploratory subgroup analyses demonstrated that NCI CTCAE Grade 3 or 4 adverse reactions were reported in more pemetrexed-treated patient who did not receive vitamin supplementation (never supplemented; N=32) compared to those who received daily folic acid and vitamin B₁₂ (fully supplemented; N=168). Selected Grade 3-4 adverse reactions that occurred in patients receiving pemetrexed in combination with cisplatin with or without full vitamin supplementation, respectively, included: neutropenia (23% versus 38%, respectively), thrombocytopenia (5% versus 9%, respectively), vomiting (11% versus 31%, respectively), febrile neutropenia (1% versus 9%, respectively), infection with Grade 3 or 4 neutropenia (0% versus 6%, respectively), and diarrhea (4% versus 9%, respectively).

IMPORTANT SAFETY INFORMATION (CONTINUED)

The following adverse reactions occurred more frequently in patients who were fully vitamin supplemented than in patients who were never supplemented: hypertension (11% versus 3%, respectively), chest pain (8% versus 6%, respectively), and thrombosis/embolism (6% versus 3%, respectively).

Additional Experience Across Clinical Trials

Sepsis, with or without neutropenia, including fatal cases occurred in 1% of patients. Severe esophagitis, resulting in hospitalization occurred in <1%.

Postmarketing Experience

The following adverse reactions have been identified during post-approval use of pemetrexed. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Immune-mediated hemolytic anemia, colitis, pancreatitis, edema, radiation recall, interstitial pneumonitis, serious and fatal bullous skin conditions, Stevens-Johnson syndrome, and toxic epidermal necrolysis were reported during post-approval use of pemetrexed.

DRUG INTERACTIONS

Effects of Ibuprofen on Pemetrexed

Ibuprofen increases exposure (AUC) of pemetrexed. In patients with creatinine clearance between 45 mL/min and 79 mL/min:

- Avoid administration of ibuprofen for 2 days before, the day of, and 2 days following administration of AXTLE™.
- Monitor patients more frequently for myelosuppression, renal, and gastrointestinal toxicity, if concomitant administration of ibuprofen cannot be avoided.

USE IN SPECIFIC POPULATIONS

Pregnancy

Risk Summary

Based on findings from animal studies and its mechanism of action, AXTLE™ can cause fetal harm when administered to a pregnant woman. There are no available data on pemetrexed use in pregnant women. In animal reproduction studies, intravenous administration of pemetrexed to pregnant mice during the period of organogenesis was teratogenic, resulting in developmental delays and malformations at doses lower than the recommended human dose of 500 mg/m². Advise pregnant women of the potential risk to a fetus.

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

Please see Important Safety Information on pages 3 and 13-19 and full [Prescribing Information](#) for AXTLE™.

IMPORTANT SAFETY INFORMATION (CONTINUED)

Data

Animal Data

Pemetrexed was teratogenic in mice. Daily dosing of pemetrexed by intravenous injection to pregnant mice during the period of organogenesis increased the incidence of fetal malformations (cleft palate; protruding tongue; enlarged or misshaped kidney; and fused lumbar vertebra) at doses (based on BSA) 0.03 times the human dose of 500 mg/m². At doses, based on BSA, greater than or equal to 0.0012 times the 500 mg/m² human dose, pemetrexed administration resulted in dose-dependent increases in developmental delays (incomplete ossification of talus and skull bone; and decreased fetal weight).

Lactation

Risk Summary

There is no information regarding the presence of pemetrexed or its metabolites in human milk, the effects on the breastfed infant, or the effects on milk production. Because of the potential for serious adverse reactions in breastfed infants from pemetrexed, advise women not to breastfeed during treatment with AXTLE™ and for one week after last dose.

Females and Males of Reproductive Potential

Based on animal data, pemetrexed can cause malformations and developmental delays when administered to a pregnant woman. Verify pregnancy status of females of reproductive potential prior to initiating AXTLE™.

Because of the potential for genotoxicity, advise females of reproductive potential to use effective contraception during treatment with AXTLE™ and for 6 months after the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with AXTLE™ and for 3 months after the last dose.

AXTLE™ may impair fertility in males of reproductive potential. It is not known whether these effects on fertility are reversible.

Pediatric Use

The safety and effectiveness of AXTLE™ in pediatric patients have not been established.

Geriatric Use

Of the 3,946 patients enrolled in clinical studies of pemetrexed, 34% were 65 and over and 4% were 75 and over. No overall differences in effectiveness were observed between these patients and younger patients. The incidences of Grade 3-4 anemia, fatigue, thrombocytopenia, hypertension, and neutropenia were higher in patients 65 years of age and older as compared to younger patients: in at least one of five randomized clinical trials.

IMPORTANT SAFETY INFORMATION (CONTINUED)

Patients with Renal Impairment

Pemetrexed is primarily excreted by the kidneys. Decreased renal function results in reduced clearance and greater exposure (AUC) to pemetrexed compared with patients with normal renal function. No dose is recommended for patients with creatinine clearance less than 45 mL/min.

OVERDOSAGE

No drugs are approved for the treatment of pemetrexed overdose. Based on animal studies, administration of leucovorin may mitigate the toxicities of pemetrexed overdosage. It is not known whether pemetrexed is dialyzable.

Please see the full [Prescribing Information](#) for safety information and dosing guidelines.

To report SUSPECTED ADVERSE REACTIONS, contact Avyxa Pharma, LLC at 1-888-520-0954 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Notes:

[illegible]

References:

1. AXTLE™ Full Prescribing Information. Parsippany, NJ. AVYXA™ Pharma. Revised December 2024.
2. Centers for Medicare & Medicaid Services (CMS). Overview of coding and classification systems. U.S. Department of Health & Human Services. Accessed December 17, 2024, from <https://www.cms.gov/cms-guide-medical-technology-companies-and-other-interested-parties/coding/overview-coding-classification-systems>
3. CMS. Healthcare Common Procedure Coding System Level II Coding Procedures 2023. Accessed December 17, 2024. <https://www.cms.gov/medicare/coding-billing/healthcare-common-procedure-system>
4. CMS. Billing and Coding: Approved Drugs and Pharmaceuticals; Includes Cancer Chemotherapeutic Agents. Revised November 2, 2023. <https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleId=53049&ver=98>
5. Current Procedural Terminology. 2024 American Medical Association.
6. CMS. Billing and Coding: JW and JZ Modifier Billing Guidelines. Article ID A55932. Revised March 21, 2024. <https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleId=55932>
7. CDC. Classification of Diseases, Functioning, and Disability. Revised June 7, 2024. <https://www.cdc.gov/nchs/icd/>
8. CDC. National Center for Health Statistics. ICD-10-CM Fiscal Year Releases. Revised April 1, 2024. <https://www.cdc.gov/nchs/icd/icd-10-cm/files.html>

